Breaking News Instant updates and real-time market news.

C

Citi

$62.81

-1.1 (-1.72%)

, GSK

GlaxoSmithKline

$40.57

-0.1 (-0.25%)

04:55
02/08/19
02/08
04:55
02/08/19
04:55

The Conference Forum to hold a conference

5th Annual Immuno-Oncology 360 will be held in New York on February 6-8.

C

Citi

$62.81

-1.1 (-1.72%)

GSK

GlaxoSmithKline

$40.57

-0.1 (-0.25%)

DNA

Bought by RHHBY

$0.00

(0.00%)

MRK

Merck

$76.82

-0.58 (-0.75%)

MEDI

Medimmune

$0.00

(0.00%)

NKTR

Nektar

$43.82

-0.51 (-1.15%)

IOVA

Iovance Biotherapeutics

$9.69

-0.16 (-1.62%)

NEO

NeoGenomics

$16.31

-0.24 (-1.45%)

FATE

Fate Therapeutics

$13.33

-0.86 (-6.06%)

MDSO

Medidata

$73.55

-1.59 (-2.12%)

NSTG

NanoString

$22.39

-0.09 (-0.40%)

NTGN

Neon Therapeutics

$5.02

-0.03 (-0.59%)

PRAH

PRA Health

$105.75

-2.25 (-2.08%)

BTAI

BioXcel Therapeutics

$8.25

0.4 (5.10%)

  • 08

    Feb

  • 11

    Feb

  • 12

    Feb

  • 14

    Feb

  • 16

    Feb

  • 19

    Feb

  • 25

    Feb

  • 02

    Apr

  • 11

    Apr

  • 18

    May

C Citi
$62.81

-1.1 (-1.72%)

01/16/19
01/16/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Citi (C) downgraded to Hold from Buy at Standpoint Research. 2. Snap (SNAP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Mark Mahaney citing the company's recent "mixed" pre-announcement and, more importantly, its latest disclosure of a "surprise" exit by its CFO Tim Stone who was on the job for less than a year. 3. Nordstrom (JWN) downgraded to Neutral from Conviction Buy at Goldman Sachs, to Neutral from Overweight at Atlantic Equities, and to Market Perform from Outperform at Telsey Advisory. 4. AB InBev (BUD) downgraded to Underperform from Hold at Jefferies with analyst Edward Mundy saying market share pressures, some of which have only recently become visible, will likely persist, and could lead to disappointment against high expectations of an emerging-led recovery. 5. HP Enterprise (HPE) downgraded to Equal Weight from Overweight at Morgan Stanley, while NetApp (NTAP) was downgraded to Underweight from Equal Weight. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/16/19
STPT
01/16/19
DOWNGRADE
STPT
Hold
Citi downgraded to Hold from Buy at Standpoint Research
01/25/19
OPCO
01/25/19
NO CHANGE
OPCO
Outperform
Bank stocks still 'resoundingly cheap,' says Oppenheimer
Oppenheimer analyst Chris Kotowski told investors in a research note that one reason he is so "incessantly bullish" on bank stocks is that investors "still so incessantly hate them." The stocks still remain resoundingly cheap at a 63% relative P/E multiple even though bank balance sheets are arguably the best they have ever been, and the business models decidedly less capital-intensive, he contends. He continues to recommend Outperform-rated Bank of America (BAC), CIT (CIT), Citi (C), Goldman (GS), Jefferies (JEF), Morgan Stanley (MS) and U.S. Bancorp (USB).
01/15/19
01/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Viacom (VIA, VIAB) upgraded to Buy from Hold at Pivotal Research with analyst Brian Wieser citing valuation. 2. Citi (C) upgraded to Outperform from Market Perform at BMO Capital with analyst James Fotheringham saying the bank's Q4 earnings and outlook were "just fine," but the stock trades "as if tragedy were nigh" at a 2-year forward multiple of 6.3-times earnings relative to the average historical valuation of 9.5-times. 3. Grainger (GWW) upgraded to Outperform from Neutral at Macquarie. 4. Helmerich & Payne (HP) upgraded to Overweight from Neutral at JPMorgan with analyst Sean Meakim saying while Helmerich is not immune from lower exploration and production spending, there is too much pessimism on the company's ability to sustain EBITDA in such an environment. 5. Akamai (AKAM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss citing his increased confidence in durable high single digit revenue growth and margins improving. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GSK GlaxoSmithKline
$40.57

-0.1 (-0.25%)

02/01/19
WELS
02/01/19
NO CHANGE
Target $46
WELS
Market Perform
Perrigo's ProAir opportunity 'may be vaporizing,' says Wells Fargo
Wells Fargo analyst David Maris noted that GlaxoSmithKline (GSK) launched an authorized generic of Ventolin on January 15 and he has now learned that Teva (TEVA) may have "surprisingly launched" an authorized generic of ProAir in response to the generic Ventolin pressure prior to Perrigo's (PRGO) approval. Pricing pressure from generic Ventolin, in addition to the launch of an authorized generic well ahead of Perrigo's own generic ProAir launch, seem to have significantly diminished Perrigo's generic ProAir opportunity, Maris tells investors. He keeps a Market Perform rating and $46 price target on Perrigo shares.
01/31/19
WELS
01/31/19
NO CHANGE
WELS
Outperform
FDA approval of Mylan's Advair 'overdue,' says Wells Fargo
Wells Fargo analyst David Maris believes that while "overdue," FDA's approval of Mylan's (MYL) generic Advair is good news. Many investors were expecting this to be further delayed, he notes, adding that he currently has $50M generic Advair in his model for Q1. The analyst believes GlaxoSmithKline (GSK) will launch an authorized generic, and with Advair's already declining revenue, the generic Advair opportunity may turn out to be a great-to-have since it shows Mylan's ability to get complex generics approved, but may not be a game changer. Maris reiterates an Outperform rating on Mylan's shares.
01/14/19
EXAN
01/14/19
DOWNGRADE
EXAN
Neutral
GlaxoSmithKline downgraded to Neutral from Outperform at Exane BNP Paribas
01/31/19
ARGS
01/31/19
UPGRADE
Target $55
ARGS
Pfizer upgraded to Buy from Hold at Argus
Argus analyst David Toung upgraded Pfizer (PFE) to Buy with a price target of $55, saying he anticipates an upward revenue inflection point in 2021 after flat sales in the second half of 2019 and first half of 2020. After cycling through Lyrica loss of exclusivity over the next year, the analyst anticipates Pfizer to benefit from optimized portfolio of assets as it completes its consumer healthcare business joint venture with GlaxoSmithKline (GSK). Toung adds that while he does not "expect major transformational deals", he does see the management pursuing "acquisitions and divestitures that improve long-term profitability".
DNA Bought by RHHBY
$0.00

(0.00%)

MRK Merck
$76.82

-0.58 (-0.75%)

01/23/19
01/23/19
DOWNGRADE
Target $80

Market Perform
Merck downgraded to Market Perform from Outperform at BMO Capital
As previously reported, BMO Capital analyst Alex Arfaei downgraded Merck to Market Perform and also lowered his Q4 earnings view to 98c from $1.12 while keeping his $80 price target on the shares. The analyst cites the company's over-dependence on Keytruda, the Street's high expectations, and his views on upcoming competitor trials combining for a more balanced risk-reward on Merck. Arfaei anticipates that Merck's revenue growth would slow after 2021 given the loss of exclusivity for Januvia, adding that the company's pipeline does not look "good enough to offset meaningful Keytruda disruptions."
02/05/19
BOFA
02/05/19
NO CHANGE
BOFA
Merck added to US 1 List, Allergan removed at BofA/Merrill
02/01/19
PIPR
02/01/19
NO CHANGE
Target $3
PIPR
Overweight
Piper says OncoSec's TAVO resensitizing anti-PD-1 progressers 'impressive'
After OncoSec (ONCS) reported updated data for the registrational KEYNOTE-695 study evaluating TAVO plus Merck's (MRK) Keytruda, Piper Jaffray analyst Edward Tenthoff noted that TAVO's ORR improved and called the fact that TAVO resensitized anti-PD-1 progressers "impressive." He reiterates an Overweight and $3 price target on OncoSec shares.
01/23/19
01/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Sector Perform at RBC Capital with analyst Joseph Spak saying the company's more "tactful messaging" conveys downward pressure to growth expectations and also sees the "realities" of Tesla becoming a volume player highlighting its "challenges to scale and deliver high volume at high ASPs/margins." 2. Lowe's (LOW) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she thinks she was previously too optimistic on Lowe's likely margin progression. 3. Williams-Sonoma (WSM) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying he believes top and bottom-line pressures will intensify in 2019. 4. Merck (MRK) downgraded to Market Perform from Outperform at BMO Capital with analyst Alex Arfaei citing the company's over-dependence on Keytruda, the Street's high expectations, and his views on upcoming competitor trials combining for a more balanced risk-reward on Merck. 5. Pfizer (PFE) and Mylan (MYL) were downgraded to Neutral from Buy at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MEDI Medimmune
$0.00

(0.00%)

NKTR Nektar
$43.82

-0.51 (-1.15%)

01/02/19
JEFF
01/02/19
INITIATION
Target $21
JEFF
Buy
Jefferies starts Synthorx with Buy rating, $21 price target
Jefferies analyst Biren Amin initiated coverage of Synthorx (THOR) with a Buy rating and $21 price target. Based on preclinical data, the analyst believes THOR-707 could have differentiated properties compared to other IL-2 therapies and may drive monotherapy efficacy. He thinks THOR-707 will have a fast follower clinical development strategy to Nektar's (NKTR) NKTR-214. Further, Amin believes Synthorx's early pipeline offers additional upside.
12/13/18
GSCO
12/13/18
INITIATION
Target $62
GSCO
Buy
Nektar initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Paul Choi started Nektar Therapeutics with a Buy rating and $62 price target. The analyst thinks data readouts over the next 12-24 months should help to rebuild the case for NKTR-214's commercial potential across an array of tumor types. Choi, whose thesis does not assume the likelihood of Nektar being acquired, sees the readouts driving a "positive reassessment of the stock."
01/23/19
MZHO
01/23/19
NO CHANGE
Target $81
MZHO
Buy
Mizuho sees 'significant upside' in Nektar shares, reiterates $81 price target
While shares of Nektar Therapeutics (NKTR) have performed strongly year-to-date, "significant upside remains," Mizuho analyst Difei Yang tells investors in a research note. A recent Nature article on IL-2 immunotherapy and new players in the field provide support for Nektar's approach to immuno-oncology, says Yang. Further, she believes the company's collaborations with large pharma, including Bristol-Myers Squibb (BMY) and Pfizer, underscore the "strong potential" of NKTR-214. With multiple data readouts expected in 2019, Yang sees "significant value" in Nektar shares. She reiterates a Buy rating on the name with an $81 price target. The stock closed yesterday down 3% to $44.76.
11/12/18
MZHO
11/12/18
NO CHANGE
Target $81
MZHO
Buy
Nektar updated data in melanoma patients encouraging, says Mizuho
Mizuho analyst Difei Yang views Nektar Therapeutics' updated data in melanoma patients over the weekend as encouraging. While the data did not meet the analyst's base-case scenario, as overall response rate remained roughly in-line with the prior data update, Yang says she's encouraged to see a deepening of responses evidenced by an increase in the number of complete responses since the last data update. She continues to see merit in the NKTR-214/Opdivo combo. Yang expects continued data updates in various tumor settings over the coming months to drive Nektar shares and keeps a Buy rating on the name with an $81 price target.
IOVA Iovance Biotherapeutics
$9.69

-0.16 (-1.62%)

02/06/19
BARD
02/06/19
INITIATION
BARD
Outperform
Iovance Biotherapeutics initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Iovance Biotherapeutics with an Outperform rating and a $29 price target. The analyst sees the company's tumor-infiltrating lymphocyte technology as potentially disruptive to the immuno-oncology space, and sees updates from the lifileucel MM Phase 2 aand from the LN-145 cervical cancer Phase 2 as positive catalysts for Iovance shares.
11/12/18
RILY
11/12/18
NO CHANGE
Target $24
RILY
Buy
Iovance lifileucel data support melanoma optimism, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar reiterates a Buy rating on Iovance Biotherapeutics with a $24 price target after the company presented Phase II lifileucel melanoma data this weekend. The analyst views the 30% confirmed overall response rate and early duration of response as "impressive" for the highly refractory post-PD-1 patients studied. The analyst says these results validate his optimism for the potentially registrational cohort 4 of lifileucel in melanoma, guided to start in early 2019.
12/31/18
RILY
12/31/18
INITIATION
Target $24
RILY
Buy
Iovance Biotherapeutics resumed with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico resumed coverage of Iovance Biotherapeutics and kept his firm's Buy rating and $24 price target on the shares.
11/06/18
WELS
11/06/18
NO CHANGE
WELS
Outperform
Iovance data supportive of potential approval, says Wells Fargo
The 38% response rate and duration greater than six months seen in this morning's abstract data for tumor-infiltrating lymphocyte therapeutic lifleucel in PD1 experienced metastatic melanoma are "highly differentiated from other cell therapies in solid tumors and supportive of potential approval if confirmed by pivotal study," Wells Fargo analyst Jim Birchenough tells investors in a research note. The analyst keeps an Outperform rating on shares of Iovance Biotherapeutics. The stock in morning trading is down 10%, or 99c, to $8.46.
NEO NeoGenomics
$16.31

-0.24 (-1.45%)

01/02/19
SPHN
01/02/19
NO CHANGE
SPHN
CBS, Global Payments, Union Pacific among Stephens' best ideas for 2019
Stephens released its Best Ideas list for 2019, noting that over the last 13 years its Best Ideas list has outperformed the Russell 2000 by an average of 300 bps. Of note, six of the firm's 30 analysts listed "cash" as their best idea for this year. Among the rest, the picks included: Landstar System (LSTR), Enova (ENVA), RealPage (RP), FMC Corporation (FMC), Avanos (AVNS), Knight-Swift (KNX), CBS (CBS), Vulcan Materials (VMC), Encompass Health (EHC), Watsco (WSO), Global Payments (GPN), O'Reilly Automotive (ORLY), NeoGenomics (NEO), Continental Resources (CLR), Union Pacific (UNP), Ametek (AME), Wintrust Financial (WTFC), Helmerich & Payne (HP), Penske Automotive (PAG), Signature Bank (SBNY), Noble Energy (NBL), Origin Bancorp (OBNK), GrubHub (GRUB) and CenterState Bank (CSFL).
01/03/19
NEED
01/03/19
INITIATION
Target $14
NEED
Buy
NeoGenomics initiated with a Buy at Needham
Needham analyst Stephen Unger started NeoGenomics with a Buy rating and $14 price target.
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
11/01/18
BNCH
11/01/18
NO CHANGE
Target $22
BNCH
Buy
NeoGenomics price target raised to $22 from $16 at Benchmark
Benchmark analyst Bruce Jackson noted that NeoGenomics reported earnings and revenue that beat his estimates and the company raised its revenue and adjusted EPS expectations. After raising both his estimates for 2018 and 2019 and raising the multiple he applies, Jackson lifted his price target on NeoGenomics shares to $22 and keeps a Buy rating on the stock.
FATE Fate Therapeutics
$13.33

-0.86 (-6.06%)

11/11/18
PIPR
11/11/18
NO CHANGE
Target $23
PIPR
Overweight
Fate Therapeutics' NK100 update at SITC 'encouraging,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Fate Therapeutics updated Phase I NK100 data and provided new details on iPSC platform expansion at SITC. NK100 activity was observed in 7/14 AML, ovarian cancer and solid tumor patients, with seven patients receiving two infusions with NK100 cell persistence through Day 21 without compromised cytotoxicity or viability, he added, highlighting that NK100 is safe with no cytokine release syndrome or neurotoxicity even after multiple doses. Tenthoff is most excited for Fate's transformative iPSC platform enabling unprecedented scalable and homogeneous manufacturing. As expected, Fate found no adventitious agents and expects the first-ever IND on iPSC-derived Natural Killer cell therapy FT500 to clear by year-end 2018, he contends. Tenthoff adds that the company is developing a pipeline of iPSC cell therapies and will file an IND on FT516 by year-end 2018. He reiterates an Overweight rating and $23 price target on the shares.
01/02/19
PIPR
01/02/19
NO CHANGE
Target $23
PIPR
Overweight
Fate Therapeutics named a 2019 top pick at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said Fate Therapeutics remains a top pick into 2019 and he reiterated his Overweight rating and $23 price target on the stock, stating that he is "most excited" about Fate's "disruptive" pipeline of 10 iNK and iT cell induced Pluripotent Stem Cell candidates. The FDA accepted the IND for Fate's first iNK candidate and he expects initial FT500 data this year to validate Fate's broader iPSC platform, Tenthoff added.
11/05/18
JEFF
11/05/18
INITIATION
Target $17
JEFF
Buy
Fate Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Fate Therapeutics with a Buy rating and $17 price target. Natural killer cells possess advantageous cytotoxic properties distinct from T cells, and have demonstrated clinical efficacy against select cancer types, Amin tells investors in a research note. The analyst says Fate "offers a unique and potentially disruptive approach."
01/03/19
PIPR
01/03/19
NO CHANGE
Target $23
PIPR
Overweight
Bristol acquisition of Celgene a positive for Fate, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes Bristol-Myers Squibb's (BMY) agreement to acquire Celgene (CELG) is in part driven by the long-term potential of cellular therapies to treat cancer. The analyst sees the deal announced this morning as a positive for Fate Therapeutics (FATE), which he notes is developing a pipeline of allogeneic and induced pluripotent stem cell natural killer and T-cell therapies. Fate is a potential acquisition target for its "rich cell therapy pipeline and platform," Tenthoff tells investors in a research note. Fate remains a top pick for Piper in 2019 and the analyst reiterates an Overweight rating on the shares with a $23 price target.
MDSO Medidata
$73.55

-1.59 (-2.12%)

01/02/19
01/02/19
NO CHANGE
Target $70

Market Perform
Leerink says expectations high for Medidata, initiates with Market Perform
As previously reported, Leerink analyst David Larsen started Medidata with a Market Perform Rating and a $70 price target. The analyst likes how the company is considered to be the premium solution with respect to clinical trial electronic data capture. But while the fundamentals of the industry and company are favorable, Larsen thinks there is significant risk to the stock. The overall market has been volatile which will pressure higher multiple stocks, and investor expectations for revenue growth are very high and any disappointment could result in a significant sell-off, he contents. Further, the analyst believes 95%-plus of biopharma already have electronic clinical solutions in place, and the market is becoming more competitive.
01/04/19
PIPR
01/04/19
NO CHANGE
Target $83
PIPR
Overweight
Medidata price target lowered to $83 from $93 at Piper Jaffray
Piper Jaffray analyst Sean Wieland lowered his price target for Medidata Solutions to $83 while keeping an Overweight rating on the name. The analyst reduced his 2019 revenue estimates to factor in management's clarifying remarks about the impact of the Shyft acquisition. Wieland continues to like the company's growth prospects, but would "tread lightly" into its 2019 guidance to be issued on the Q4 earnings call.
12/13/18
JPMS
12/13/18
DOWNGRADE
Target $74
JPMS
Underweight
Medidata downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Sterling Auty downgraded Medidata Solutions to Underweight with an unchanged price target of $74. The analyst points out that only 2% upside remains to his fair value price target. Medidata needs to see improved execution consistency in sales to drive up estimates, Auty tells investors in a research note.
01/02/19
LEER
01/02/19
INITIATION
LEER
Market Perform
Medidata initiated with a Market Perform at Leerink
NSTG NanoString
$22.39

-0.09 (-0.40%)

10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
10/09/18
UBSW
10/09/18
INITIATION
Target $23
UBSW
Buy
NanoString initiated with a Buy at UBS
UBS analyst Daniel Brennan initiated NanoString with a Buy rating and $23 price target.
09/13/18
JPMS
09/13/18
NO CHANGE
Target $20
JPMS
Overweight
NanoString price target raised to $20 from $17 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for NanoString to $20 after hosting a dinner with management. The analyst came away "impressed" at the degree of customer interest in digital spatial profiling, now branded GeoMx, ahead of commercial launch in the first half of 2019. He cites management's "bullish tone around the launch" for his target bump and keeps an Overweight rating on NanoString.
NTGN Neon Therapeutics
$5.02

-0.03 (-0.59%)

07/23/18
BOFA
07/23/18
INITIATION
Target $18
BOFA
Buy
Neon Therapeutics initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Ying Huang initiated Neon Therapeutics with a Buy and $18 price target. Huang sees a large market opportunity for Neon's personalized and "off-the-shelf" anti-cancer therapies, but notes theses therapies are in their infancy.
07/23/18
MSCO
07/23/18
INITIATION
Target $23
MSCO
Overweight
Neon Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison initiated Neon Therapeutics with an Overweight rating and $23 price target, as he views neoantigens as a relevant target that could improve the efficacy of current checkpoint inhibitors and believes initial data demonstrates an impact on the tumor. He sees 2019 as a pivotal year for Neon and expects followup from the initial data to drive outperformance, Harrison tells investors.
07/23/18
OPCO
07/23/18
INITIATION
Target $20
OPCO
Outperform
Neon Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Neon Therapeutics with an Outperform rating and $20 price target. The analyst estimates that Neon Therapeutics will first have product revenue in 2024 resulting in total revenue that year of $676.8M, potentially growing to $3.67B in 2025, if NEO-PV-01 is successful in currently planned indications.
10/01/18
LTCO
10/01/18
INITIATION
Target $20
LTCO
Buy
Neon Therapeutics initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started Neon Therapeutics with a Buy rating and $20 price target. The analyst believes NEO-PV-01 "enjoys a powerful first mover advantage" in neoantigen therapies for improving both the depth and breadth of response of checkpoint inhibitors.
PRAH PRA Health
$105.75

-2.25 (-2.08%)

11/01/18
BARD
11/01/18
NO CHANGE
Target $119
BARD
Outperform
PRA Health weakness a buying opportunity, says Baird
Baird analyst Eric Coldwell believes the smart investor will use the weakness in PRA Health as a buying opportunity. The analyst noted Q3 revenue slowed to its slowest since the company went public, but he said it was forecasted and said it was against "incredible" comps. Other than the revenues, margins, profitability, and bookings all beat and seemed solid, said Coldwell, who reiterated his Outperform rating and $119 price target on PRA Health shares.
11/28/18
KEYB
11/28/18
NO CHANGE
KEYB
KeyBanc sees Amazon entry having little near-term impact on HCIT space
The announcement that Amazon.com (AMZN) is developing Software-as-a-Service analytical tools for the U.S. healthcare industry called Amazon Comprehend Medical will likely bring a "lot of noise, but little real, near-term financial impact" to the publicly traded Healthcare Technology and Services space, KeyBanc analyst Donald Hooker tells investors in a research note. He believes companies potentially most relevant to Amazon's announcement include Allscripts Healthcare Solutions (MDRX), Cerner (CERN), Evolent Health (EVH), Inovalon Holdings (INOV), IQVIA Holdings (IQV), Medidata Solutions (MDSO), PRA Health Sciences (PRAH), Premier (PINC), and Teladoc Health (TDOC). Hooker argues that any potential success by mega-tech companies, such as Amazon, to develop useful SaaS analytical tools "could actually empower traditional HCIT and biopharma outsourcing companies." Further, he sees a number of "unique barriers" for "big data" solutions in clinical decision support and population health management.
11/05/18
RHCO
11/05/18
NO CHANGE
Target $120
RHCO
Buy
PRA Health price target raised to $120 from $110 at SunTrust
SunTrust analyst Sandy Draper raised his price target on PRA Health to $120 after its "solid" Q3 results, saying the top-line miss was driven by the slower backlog burn from its business mix. The analyst expects the backlog burn to trough and gradually improve in 2019, adding that that the company's 1.28-times book-to-bill ratio highlights its prospects. Draper keeps his Buy rating on PRA Health.
BTAI BioXcel Therapeutics
$8.25

0.4 (5.10%)

05/03/18
05/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. nVent Electric (NVT) initiated with a Neutral at Goldman Sachs and a Perform at Oppenheimer. 2. Apergy (APY) initiated with an Outperform at Evercore ISI. 3. BioXcel Therapeutics (BTAI) initiated with a Buy at H.C. Wainwright. 4. CytRx (CYTR) assumed with a Buy at H.C. Wainwright. 5. Lithium Americas (LAC) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/18
HCWC
12/05/18
NO CHANGE
Target $25
HCWC
Buy
BioXcel Therapeutics data establish proof-of-concept, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju reiterates a Buy rating on BioXcel Therapeutics with a $25 price target after the company reported that its Phase 1b dose-ranging study of IV form of BXCL501 met the primary endpoint, with 90% of the 10 schizophrenic patients enrolled reaching a Richmond Agitation-Sedation Scale score of -1 without any significant adverse effects being observed. These data provide confirmation that BXCL501 effectively produces arousable sedation in both schizophrenic and bipolar patients, Selvaraju tells investors in a research note. The analyst anticipates that the Phase 1b data in Alzheimer's disease patients, slated for release in the coming weeks, is likely to similarly provide proof-of-concept referential evidence of sedation, albeit perhaps with a different pharmacokinetic profile.
04/02/18
04/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Karyopharm (KPTI) assumed with an Outperform at Leerink. 2. BioXcel Therapeutics (BTAI) was initiated with a Buy at Canaccord and UBS, an Outperform at BMO Capital, and an Overweight at Barclays. 3. New York & Co. (NWY) initiated with a Buy at Roth Capital. 4. Sellas Life Sciences (SLS) initiated with a Buy at H.C. Wainwright. 5. Hanesbrands (HBI) initiated with a Neutral at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/18
HCWC
05/03/18
INITIATION
Target $25
HCWC
Buy
BioXcel Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started BioXcel Therapeutics with a Buy rating and $25 price target. The analyst believes BXCL701 could be incorporated into multiple future I/O combination regimens.

TODAY'S FREE FLY STORIES

CVM

CEL-SCI

$6.22

-0.38 (-5.76%)

09:35
07/23/19
07/23
09:35
07/23/19
09:35
Hot Stocks
CEL-SCI announces review published in International Immunopharmacology »

CEL-SCI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$132.94

0.57 (0.43%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Hot Stocks
United Technologies says 'very confident' about updated FY19 guidance »

Says: More good things to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PKX

Posco

$49.91

-0.26 (-0.52%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Upgrade
Posco rating change  »

Posco upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

TRPX

Therapix Biosciences

$2.32

-0.02 (-0.85%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Hot Stocks
Therapix Biosciences signs LOI to merge with Destiny Biosciences »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

09:32
07/23/19
07/23
09:32
07/23/19
09:32
Recommendations
Amazon.com analyst commentary at BMO Capital »

Amazon.com Q3 consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UGP

Ultrapar

$5.23

-0.165 (-3.06%)

09:32
07/23/19
07/23
09:32
07/23/19
09:32
Upgrade
Ultrapar rating change  »

Ultrapar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$34.25

-0.62 (-1.78%)

09:31
07/23/19
07/23
09:31
07/23/19
09:31
Hot Stocks
Breaking Hot Stocks news story on Harley-Davidson »

Harley-Davidson sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SEMG

SemGroup

$11.92

0.13 (1.10%)

09:31
07/23/19
07/23
09:31
07/23/19
09:31
Upgrade
SemGroup rating change  »

SemGroup upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

HOG

Harley-Davidson

$34.25

-0.62 (-1.78%)

09:28
07/23/19
07/23
09:28
07/23/19
09:28
Hot Stocks
Harley-Davidson continues to see FY19 annual cash savings of $25M-$30M »

Sees FY20 annual cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

09:28
07/23/19
07/23
09:28
07/23/19
09:28
Hot Stocks
Breaking Hot Stocks news story on Marinus Pharmaceuticals »

Marinus drops 66% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$27.84

-0.11 (-0.39%)

09:25
07/23/19
07/23
09:25
07/23/19
09:25
Hot Stocks
Fifth Third says it continues to see a generally healthy economic backdrop »

Says wants to leverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

BIDU

Baidu

$111.74

-0.5 (-0.45%)

09:25
07/23/19
07/23
09:25
07/23/19
09:25
Downgrade
Baidu rating change  »

Baidu downgraded to Mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

PLCE

Children's Place

$91.41

-7.96 (-8.01%)

09:24
07/23/19
07/23
09:24
07/23/19
09:24
Recommendations
Children's Place analyst commentary at DA Davidson »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.97

0.03 (1.02%)

, COWN

Cowen Group

$15.87

-0.23 (-1.43%)

09:23
07/23/19
07/23
09:23
07/23/19
09:23
Conference/Events
National Cannabis Industry Association to hold a summit »

Cannabis Business Summit…

LTS

Ladenburg Thalmann

$2.97

0.03 (1.02%)

COWN

Cowen Group

$15.87

-0.23 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

MORN

Morningstar

$153.65

-0.5 (-0.32%)

, NTRS

Northern Trust

$92.76

-0.09 (-0.10%)

09:21
07/23/19
07/23
09:21
07/23/19
09:21
Conference/Events
CFA Institute to hold a seminar »

CFA Institute Seminar for…

MORN

Morningstar

$153.65

-0.5 (-0.32%)

NTRS

Northern Trust

$92.76

-0.09 (-0.10%)

JPM

JPMorgan

$114.31

0.77 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 01

    Aug

  • 06

    Aug

ZG

Zillow

$47.20

0.36 (0.77%)

, Z

Zillow

$47.41

0.27 (0.57%)

09:20
07/23/19
07/23
09:20
07/23/19
09:20
Recommendations
Zillow, Zillow, Realogy, Amazon.com analyst commentary at Craig-Hallum »

Zillow weakness on…

ZG

Zillow

$47.20

0.36 (0.77%)

Z

Zillow

$47.41

0.27 (0.57%)

RLGY

Realogy

$5.17

-0.08 (-1.52%)

AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 07

    Aug

  • 07

    Aug

  • 08

    Aug

TRPX

Therapix Biosciences

$2.32

-0.02 (-0.85%)

09:20
07/23/19
07/23
09:20
07/23/19
09:20
Hot Stocks
Breaking Hot Stocks news story on Therapix Biosciences »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
07/23/19
07/23
09:18
07/23/19
09:18
Options
Overnight activity included 219 trades in SPX and 6 trades in VIX »

219 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$37.58

0.81 (2.20%)

09:17
07/23/19
07/23
09:17
07/23/19
09:17
Recommendations
Twitter analyst commentary at BMO Capital »

Twitter's delayed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 30

    Jul

REAL

RealReal

$24.84

0.69 (2.86%)

09:17
07/23/19
07/23
09:17
07/23/19
09:17
Initiation
RealReal initiated at BofA/Merrill »

RealReal initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

TECH

Bio-Techne

$208.62

-0.61 (-0.29%)

09:17
07/23/19
07/23
09:17
07/23/19
09:17
Hot Stocks
Bio-Techne and Uman Diagnostic announce agreement »

Uman Diagnostics, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 13

    Nov

ATEC

Alphatec

$4.60

0.1 (2.22%)

09:16
07/23/19
07/23
09:16
07/23/19
09:16
Hot Stocks
Alphatec announces commercial launch of InVictus spinal fixation platform »

Alphatec Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Sep

AMRH

AMERI Holdings

$0.34

-0.0098 (-2.80%)

, GOOG

Alphabet

$1,138.09

8.09 (0.72%)

09:15
07/23/19
07/23
09:15
07/23/19
09:15
Hot Stocks
AMERI Holdings advances Google partnership »

AMERI Holdings (AMRH)…

AMRH

AMERI Holdings

$0.34

-0.0098 (-2.80%)

GOOG

Alphabet

$1,138.09

8.09 (0.72%)

GOOGL

Alphabet Class A

$1,139.52

7.85 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 03

    Aug

  • 08

    Aug

  • 27

    Oct

09:15
07/23/19
07/23
09:15
07/23/19
09:15
General news
U.S. FHFA Home Price index rose 0.1% to 275.0 in May »

U.S. FHFA Home Price…

FCBP

First Choice Bank

$22.80

0.03 (0.13%)

09:14
07/23/19
07/23
09:14
07/23/19
09:14
Earnings
First Choice Bank announces Q1 EPS 58c, one est. 54c »

"Our larger scale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.